Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Apr 25;63(5):e00014-19.
doi: 10.1128/AAC.00014-19. Print 2019 May.

Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants

Robert A Smith  1 , Dana N Raugi  2 , Vincent H Wu  2 , Christopher G Zavala  2 , Jennifer Song  2 , Khardiata Mbaye Diallo  3 , Moussa Seydi  3 , Geoffrey S Gottlieb  2   4 ; University of Washington-Dakar HIV-2 Study Group
Collaborators, Affiliations

Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants

Robert A Smith et al. Antimicrob Agents Chemother. .

Abstract

We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based antiretroviral therapy should be evaluated in HIV-2-infected individuals.

Keywords: HIV treatment; HIV-2; West Africa; antiretroviral therapy; bictegravir; drug resistance; human immunodeficiency virus; integrase.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Antiviral activity of bictegravir against HIV-1NL4-3 and HIV-2ROD9 in MAGIC-5A cells. Error bars indicate ±1 SD and, when not visible, are smaller than the symbols. (A) Results from a single assay in which HIV-1NL4-3 and HIV-2ROD9 were tested head to head. Data points represent the amount of β-galactosidase activity produced in HIV-infected bictegravir-treated cultures relative to HIV-infected solvent-only (i.e., no-drug) controls. Each point is the mean of two cultures that were maintained in parallel. Curves were generated using a sigmoidal regression equation (GraphPad Prism 6.0 software). (B) EC50 values from seven independent runs of the single-cycle assay in which HIV-1NL4-3 and HIV-2ROD9 were tested head to head. P value is the result of a paired t test.
FIG 2
FIG 2
Summary of the activity of bictegravir against HIV-1 and HIV-2 isolates in MAGIC-5A cells. (A) Comparison of the EC50 values for group A and group B isolates of HIV-2. (B) Comparison of all EC50 values for HIV-1 and HIV-2. Each point represents the mean EC50 for a single virus isolate. Filled squares and circles indicate the EC50 values for HIV-1NL4-3 and HIV-2ROD9, respectively. Horizontal lines indicate the mean EC50 values for each grouping. P values are from Welch’s t tests.
See this image and copyright information in PMC

References

    1. Gottlieb GS, Raugi DN, Smith RA. 2018. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV 5:e390–e399. doi:10.1016/S2352-3018(18)30094-8. - DOI - PubMed
    1. de Silva TI, Cotten M, Rowland-Jones SL. 2008. HIV-2: the forgotten AIDS virus. Trends Microbiol 16:588–595. doi:10.1016/j.tim.2008.09.003. - DOI - PubMed
    1. Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. 2016. HIV-2 molecular epidemiology. Infect Genet Evol 46:233–240. doi:10.1016/j.meegid.2016.08.010. - DOI - PubMed
    1. Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, Christopherson C, Biberfeld G, Albert J. 2000. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Arch Intern Med 160:3286–3293. doi:10.1001/archinte.160.21.3286. - DOI - PubMed
    1. De Cock KM, Odehouri K, Colebunders RL, Adjorlolo G, Lafontaine MF, Porter A, Gnaore E, Diaby L, Moreau J, Heyward WL. 1990. A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, Cote d'Ivoire. AIDS 4:443–448. doi:10.1097/00002030-199005000-00010. - DOI - PubMed

Publication types